FNN Content / Shares / Video

September 25, 2023

New World Metals Conference: Sky Metals

By Paul Sanger | More Articles by Paul Sanger

 

Vertical Events is the premier mining, resources and technology conference organising company in Australia. Since establishment in 1998, Vertical Events has organised and implemented some of the largest and most renowned conferences in the country. Wally Graham of Resources Roadhouse at the New World Metals Conference, speaking with Oliver Davies, CEO of Sky Metals (ASX:SKY).

Sky Metals Limited is an ASX listed public company focused on the development and exploration of mineral resources in Australia. SKY’s project portfolio offers exposure to the tin market, where a long term growth in prices reflects challenged supply and growing demand amid new applications of the metal.

About Paul Sanger

Investment Banking Executive with over 30 years of experience focused on global capital markets. He is the former Managing Director and Head of Distribution and Corporate access (Asia) for Citi, where he managed and maintained a team of over 350 financial market professionals across 10 countries in public capital markets. Paul has a long background dealing with the senior management of listed and unlisted corporations on public market strategy and has extensive experience in the entire lifespan of a publicly listed entity, including IPOs, mergers and acquisitions, asset purchases and sales, restructures and capital raises. He is a proven leader and business strategist with an intimate knowledge of financial markets and corporate governance issues.

View more articles by Paul Sanger →

More Related Articles

Hawkish Fed tilt, More spending in MYEFO, PMIs point to lower inflation ahead, Wealth boost to slow

Hot Stocks: Exosome Breakthrough, Gas Pipeline Deals and More

Landfill gold: Cleanaway’s trash-for-cash deal

Wesfarmers to sell Coregas for $770m to Nippon Sanso Holdings

Ventia secures $2bn deal with Telstra for digital infrastructure support

Radiopharm gets green light for Phase 1 cancer trial